$LAB
STANDARD BIOTOOLS INC.

2023 Q2 Form 10-Q Financial Statement

#000116219423000024 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $27.67M $25.12M $26.50M
YoY Change 47.34% -5.23% -19.18%
Cost Of Revenue $14.06M $13.00M $14.27M
YoY Change -1.99% -8.92% 3.74%
Gross Profit $13.60M $12.12M $12.24M
YoY Change 207.25% -0.92% -35.73%
Gross Profit Margin 49.17% 48.27% 46.17%
Selling, General & Admin $22.60M $22.31M $30.88M
YoY Change -25.62% -27.75% 11.83%
% of Gross Profit 166.15% 184.0% 252.31%
Research & Development $6.184M $6.409M $8.865M
YoY Change -50.94% -27.7% -17.56%
% of Gross Profit 45.46% 52.86% 72.44%
Depreciation & Amortization $3.626M $3.662M $3.971M
YoY Change -5.45% -7.78% 1.38%
% of Gross Profit 26.66% 30.2% 32.45%
Operating Expenses $31.05M $41.71M $54.01M
YoY Change -27.77% -22.77% 3.63%
Operating Profit -$17.45M -$16.59M -$27.50M
YoY Change -54.75% -39.67% 42.36%
Interest Expense $1.129M $1.117M $1.030M
YoY Change -104.83% 8.45% 16.12%
% of Operating Profit
Other Income/Expense, Net $1.839M $1.130M $118.0K
YoY Change -156.79% 857.63% -141.4%
Pretax Income -$16.74M -$16.58M -$76.86M
YoY Change -74.31% -78.43% 275.08%
Income Tax $300.0K $300.0K -$600.0K
% Of Pretax Income
Net Earnings -$17.04M -$16.84M -$76.29M
YoY Change -73.18% -77.92% 305.33%
Net Earnings / Revenue -61.59% -67.05% -287.84%
Basic Earnings Per Share -$0.22 -$0.21 -$0.99
Diluted Earnings Per Share -$0.22 -$0.21 -$0.99
COMMON SHARES
Basic Shares Outstanding 78.38M shares 79.06M shares 77.03M shares
Diluted Shares Outstanding 78.67M shares 79.08M shares 77.03M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.3M $154.5M $29.98M
YoY Change -32.62% 415.42% -39.73%
Cash & Equivalents $142.3M $113.7M $29.98M
Short-Term Investments $0.00 $40.87M
Other Short-Term Assets $3.567M $3.374M $4.547M
YoY Change -39.93% -25.8% -51.0%
Inventory $22.08M $22.51M $23.25M
Prepaid Expenses
Receivables $15.12M $14.50M $15.42M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $183.1M $194.9M $73.20M
YoY Change -27.03% 166.31% -24.01%
LONG-TERM ASSETS
Property, Plant & Equipment $24.52M $25.00M $27.70M
YoY Change -60.88% -9.74% 16.46%
Goodwill $106.3M $106.3M $106.3M
YoY Change -0.05% -0.12%
Intangibles $7.000M $9.800M $24.88M
YoY Change -60.6% -32.77%
Long-Term Investments
YoY Change
Other Assets $2.754M $2.665M $3.445M
YoY Change 22.89% -22.64% -21.45%
Total Long-Term Assets $172.8M $176.7M $198.7M
YoY Change -9.19% -11.08% -4.85%
TOTAL ASSETS
Total Short-Term Assets $183.1M $194.9M $73.20M
Total Long-Term Assets $172.8M $176.7M $198.7M
Total Assets $355.8M $371.7M $271.9M
YoY Change -19.34% 36.67% -10.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.089M $6.109M $12.52M
YoY Change -32.46% -51.19% -0.28%
Accrued Expenses $7.176M $6.878M $7.589M
YoY Change -61.45% -9.37% -49.53%
Deferred Revenue $11.69M $11.64M $12.29M
YoY Change -5.33% -13.58%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.583M $3.333M $0.00
YoY Change
Total Short-Term Liabilities $46.84M $43.79M $47.17M
YoY Change 9.52% -7.18% -11.87%
LONG-TERM LIABILITIES
Long-Term Debt $60.66M $61.73M $100.0M
YoY Change -6.02% -38.29% 85.81%
Other Long-Term Liabilities $843.0K $550.0K $1.494M
YoY Change -98.56% -63.19% 8.73%
Total Long-Term Liabilities $843.0K $550.0K $1.494M
YoY Change -99.31% -63.19% 8.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.84M $43.79M $47.17M
Total Long-Term Liabilities $843.0K $550.0K $1.494M
Total Liabilities $158.0M $157.6M $249.8M
YoY Change -5.6% -36.93% 37.07%
SHAREHOLDERS EQUITY
Retained Earnings -$960.0M -$942.9M -$812.3M
YoY Change 16.08% 16.78%
Common Stock $81.00K $80.00K $77.00K
YoY Change 3.9% 2.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$113.4M -$97.15M $22.11M
YoY Change
Total Liabilities & Shareholders Equity $355.8M $371.7M $271.9M
YoY Change -19.34% 36.67% -10.9%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$17.04M -$16.84M -$76.29M
YoY Change -73.18% -77.92% 305.33%
Depreciation, Depletion And Amortization $3.626M $3.662M $3.971M
YoY Change -5.45% -7.78% 1.38%
Cash From Operating Activities -$9.329M -$8.485M -$15.59M
YoY Change -68.89% -45.57% 20.84%
INVESTING ACTIVITIES
Capital Expenditures $838.0K $1.010M $868.0K
YoY Change -189.34% 16.36% -87.46%
Acquisitions
YoY Change
Other Investing Activities $40.96M $44.16M $0.00
YoY Change -129.83% -100.0%
Cash From Investing Activities $40.13M $43.15M -$868.0K
YoY Change -129.03% -5071.66% -82.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities -2.084M -$2.558M $18.08M
YoY Change -100.98% -114.15% -1861.7%
NET CHANGE
Cash From Operating Activities -9.329M -$8.485M -$15.59M
Cash From Investing Activities 40.13M $43.15M -$868.0K
Cash From Financing Activities -2.084M -$2.558M $18.08M
Net Change In Cash 28.71M $32.13M $1.532M
YoY Change -35.81% 1997.52% -108.16%
FREE CASH FLOW
Cash From Operating Activities -$9.329M -$8.485M -$15.59M
Capital Expenditures $838.0K $1.010M $868.0K
Free Cash Flow -$10.17M -$9.495M -$16.46M
YoY Change -65.0% -42.31% -16.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001162194
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P9M
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-34180
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
STANDARD BIOTOOLS INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0513190
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Tower Place, Ste 2000
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco,
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
266-6000
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
LAB
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78384944 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113663000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
40874000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
84475000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
318000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
592000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14504000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17280000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
22513000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
21473000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3374000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4278000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
194928000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
208815000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25002000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25652000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32974000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33883000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2665000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3109000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9800000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12600000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
106285000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
106251000 usd
CY2023Q1 us-gaap Assets
Assets
371654000 usd
CY2022Q4 us-gaap Assets
Assets
390310000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6109000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7914000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8430000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9153000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3764000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3682000 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11636000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10792000 usd
CY2023Q1 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3637000 usd
CY2022Q4 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3644000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6878000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6175000 usd
CY2023Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
3333000 usd
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2083000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43787000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43443000 usd
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54733000 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54615000 usd
CY2023Q1 us-gaap Secured Long Term Debt
SecuredLongTermDebt
7001000 usd
CY2022Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
8194000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1052000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1055000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33151000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34081000 usd
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3828000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3816000 usd
CY2023Q1 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
13452000 usd
CY2022Q4 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
14359000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
550000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
961000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
157554000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
160524000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000 shares
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000 shares
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000 shares
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000 shares
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000 shares
CY2023Q1 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000 usd
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000 usd
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80324000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79904000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78652000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79482000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
80000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
80000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
850063000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
847008000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1328000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1896000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-942939000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-926096000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1672000 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
422000 shares
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3029000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
563000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97153000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
371654000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
390310000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25119000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26504000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6409000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8865000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22308000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30875000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
41712000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
54007000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16593000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27503000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1117000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
1030000 usd
CY2023Q1 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0 usd
CY2022Q1 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
37792000 usd
CY2023Q1 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0 usd
CY2022Q1 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-10655000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1130000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16580000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-76862000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
398000 usd
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
263000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-574000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-76288000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79080000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79080000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77031000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77031000 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-76288000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
170000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-150000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
568000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16275000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76438000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-93000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3148000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2466000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
568000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97153000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94596000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-87000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4042000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-76288000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14600000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22113000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-76288000 usd
CY2023Q1 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0 usd
CY2022Q1 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
37792000 usd
CY2023Q1 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0 usd
CY2022Q1 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-10655000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3148000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4042000 usd
CY2023Q1 lab Amortization Of Developed Technology Rights
AmortizationOfDevelopedTechnologyRights
2800000 usd
CY2022Q1 lab Amortization Of Developed Technology Rights
AmortizationOfDevelopedTechnologyRights
2968000 usd
CY2023Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
862000 usd
CY2022Q1 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1003000 usd
CY2023Q1 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
350000 usd
CY2022Q1 us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
851000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
204000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
211000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-314000 usd
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
104000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3027000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2917000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1087000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3558000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-955000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
38000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1835000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1905000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
-754000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
3037000 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
804000 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
155000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
198000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1346000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8485000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15590000 usd
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6836000 usd
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 usd
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
51000000 usd
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
0 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1010000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
868000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43154000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-868000 usd
CY2023Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
25000000 usd
CY2023Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0 usd
CY2022Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
6838000 usd
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2466000 usd
CY2022Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
92000 usd
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3600000 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
87000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2558000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18075000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-85000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
32134000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1532000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29467000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114458000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30999000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
232000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
102000 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
306000 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
488000 usd
CY2023Q1 lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
32000 usd
CY2022Q1 lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
-133000 usd
CY2023Q1 lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
726000 usd
CY2022Q1 lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
722000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. We base our estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. We assessed certain accounting matters that generally require consideration of forecasted financial information, including the impact of geopolitical factors, including the war in Ukraine; inflation; and the possibility of a global economic recession. These accounting matters included but were not limited to inventory and related reserves; the carrying value of goodwill and other long-lived assets; and the potential outcome of uncertain tax positions that have been recognized in our consolidated financial statements or tax returns. We also use significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on our condensed consolidated financial statements.</span></div>
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14624000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7988000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
75164000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
66176000 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
113505000 shares
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
103894000 shares
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25119000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26504000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25119000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26504000 usd
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
15500000 usd
CY2023Q1 lab Contract With Customer Liability Increase From Cash Receipts
ContractWithCustomerLiabilityIncreaseFromCashReceipts
4500000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
11157000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
6912000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3752000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1904000 usd
CY2023Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
23725000 usd
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3100000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
8803000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1407000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10210000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113663000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
795000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1015000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114458000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000 usd
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
16016000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
16866000 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
831000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
945000 usd
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13428000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
15245000 usd
CY2023Q1 us-gaap Inventory Gross
InventoryGross
30275000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
33056000 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7762000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
11583000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
22513000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
21473000 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54039000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53069000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30611000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29029000 usd
CY2023Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1574000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1612000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25002000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25652000 usd
CY2023Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1798000 usd
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1170000 usd
CY2023Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2820000 usd
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2795000 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1438000 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1193000 usd
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
595000 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
775000 usd
CY2023Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1779000 usd
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3220000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8430000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9153000 usd
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Maximum Contract Value
ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue
34000000 usd
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Capital Expenditures
ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures
22200000 usd
CY2023Q1 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
900000 usd
CY2022Q1 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
800000 usd
CY2023Q1 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
5100000 usd
CY2022Q4 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
4200000 usd
CY2023Q1 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
17100000 usd
CY2022Q4 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
18000000 usd
CY2023Q1 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3637000 usd
CY2022Q4 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3644000 usd
CY2023Q1 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
13452000 usd
CY2022Q4 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
14359000 usd
CY2023Q1 lab Deferred Grant Revenue
DeferredGrantRevenue
17089000 usd
CY2022Q4 lab Deferred Grant Revenue
DeferredGrantRevenue
18003000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33151000 usd
CY2022Q1 us-gaap Share Price
SharePrice
2.84
CY2022Q1 us-gaap Share Price
SharePrice
3.59
CY2023Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q1 lab Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
43928000 usd
CY2022Q4 lab Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
44314000 usd
CY2023Q1 lab Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
10954000 usd
CY2022Q4 lab Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
10431000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32974000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33883000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3764000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3682000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34081000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
36915000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
37763000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y7M6D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y9M18D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.118
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.118
CY2023Q1 lab Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
155436000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
104000 usd
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
155332000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113663000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
40874000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
795000 usd
CY2022Q4 lab Cash Cash Equivalents And Short Term Investments Amortized Cost
CashCashEquivalentsAndShortTermInvestmentsAmortizedCost
167301000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
502000 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
166799000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
84475000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1015000 usd
CY2023Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
65578000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
65578000 usd
CY2022Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1250484 shares
CY2023Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2500000 usd
CY2023Q1 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
1.97
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1672793 shares
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3000000 usd
CY2023Q1 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
17000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.92
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6745000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7882000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.43
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
947000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.05
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
822000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.72
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8007000 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28000 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
741000 shares
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
5.92
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne
P6Y2M12D
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue
19000 usd
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
7266000 shares
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
3.71
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2023Q1 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
9000 usd
CY2023Q1 us-gaap Share Price
SharePrice
1.95
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3148000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4042000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000 usd
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.016
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
CY2022Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25119000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26504000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16593000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27503000 usd
CY2023Q1 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
2000000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
3239000 usd
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
357000 usd
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
1779000 usd
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
1817000 usd
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
357000 usd
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
357000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
lab-20230331_pre.xml Edgar Link unprocessable
0001162194-23-000024-index-headers.html Edgar Link pending
0001162194-23-000024-index.html Edgar Link pending
0001162194-23-000024.txt Edgar Link pending
0001162194-23-000024-xbrl.zip Edgar Link pending
exhibit101-sbi_firstdata.htm Edgar Link pending
exhibit101-sbi_firstdata001.jpg Edgar Link pending
exhibit101-sbi_firstdata002.jpg Edgar Link pending
exhibit101-sbi_firstdata003.jpg Edgar Link pending
exhibit101-sbi_firstdata004.jpg Edgar Link pending
exhibit101-sbi_firstdata005.jpg Edgar Link pending
exhibit101-sbi_firstdata006.jpg Edgar Link pending
exhibit101-sbi_firstdata007.jpg Edgar Link pending
exhibit101-sbi_firstdata008.jpg Edgar Link pending
exhibit101-sbi_firstdata009.jpg Edgar Link pending
exhibit101-sbi_firstdata010.jpg Edgar Link pending
exhibit101-sbi_firstdata011.jpg Edgar Link pending
exhibit101-sbi_firstdata012.jpg Edgar Link pending
exhibit101-sbi_firstdata013.jpg Edgar Link pending
exhibit101-sbi_firstdata014.jpg Edgar Link pending
exhibit101-sbi_firstdata015.jpg Edgar Link pending
exhibit31110q1q2023.htm Edgar Link pending
exhibit31210q1q2023.htm Edgar Link pending
exhibit32110q1q2023.htm Edgar Link pending
exhibit32210q1q2023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lab-20230331.htm Edgar Link pending
lab-20230331.xsd Edgar Link pending
lab-20230331_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
lab-20230331_cal.xml Edgar Link unprocessable
lab-20230331_def.xml Edgar Link unprocessable
lab-20230331_lab.xml Edgar Link unprocessable
lab-20230331_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending